HSCI RESEARCH SEMINAR SERIES
SCHOOL OF HEALTH SCIENCES

DECIPHERING ALZHEIMER’S DISEASE HETEROGENEITY – A PATH TOWARDS PRECISION MEDICINE

DR. LIANA G. APOSTOLOVA, MD, MSc
The Barbara and Peer Baekgaard Professor in Alzheimer's Disease Research and Professor in Neurology, Radiology, Medical and Molecular Genetics at the IU School of Medicine.

Tuesday, January 28, 2020
BRNG 2280
4:30 p.m.

Abstract:

Dr. Apostolova will review the clinical and biomarker heterogeneity in Alzheimer’s disease. The focus will be predominantly on imaging biomarkers – MRI, amyloid and tau PET being the main modalities. Dr Apostolova will discuss the role that imaging genetics can play in improving our understanding of AD heterogeneity and AD risk overall. She will also present the Longitudinal Early Onset AD Study - a US-wide multisite consortium focused on improving our understanding of early onset AD and describe its potential to advance our field towards precision medicine.

The Longitudinal Early-onset AD Study (LEADS) is funded by the National Institute on Aging (NIA) to address several major gaps in Alzheimer’s disease and related dementias research. LEADS is an observational study that will enroll and follow 600 cognitively impaired participants and 100 cognitively normal participants ages 40-64 years at approximately 18 sites in the United States. Clinical, cognitive, imaging (MRI, amyloid and tau PET), fluid biomarkers (Blood and CSF), and genetic characteristics (DNA, RNA, DNA methylation) will be assessed. The primary goal of LEADS is to develop sensitive clinical and biomarker measures for future clinical and research use.